Metrics as of 10/17/2026, 05:07 AM (Berlin time), refresh in progress.
Heidelberg Pharma Stock
Heidelberg Pharma AG
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Germany
- CEO
- Dongzhou Liu
- Employees
- 41
- Market cap
- €103 M
- IPO
- 13/11/2006
Heidelberg Pharma AG is a healthcare biotechnology company headquartered in Ladenburg, Germany. Founded in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017. The firm focuses on oncology, specifically emphasizing its innovative antibody-targeted amanitin…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Heidelberg Pharma stock: price history
1D
-3.9%
1W
-1.3%
1M
-13.7%
6M
-20.0%
YTD
-11.3%
1Y
-28.6%
2Y
-17.0%
5Y
-59.3%
10Y
+45.7%
Next earnings date
Next earnings date
03/02/2027 (in 109 days)
Volatility around earnings
~8% stronger price swings than usual
Ask the agents about Heidelberg Pharma
Heidelberg Pharma stock metrics
P/E
-3.44
P/B
-6.95
EV/EBITDA
-2.93
RETURN ON EQUITY
0.0%
NET MARGIN
-274.1%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
31/08/2026
Free float & liquidity
FREE FLOAT
21.0%
FLOAT SHARES
9,824,703
AVG. DAILY VOLUME (30D)
5,122
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Heidelberg Pharma stock
What does Heidelberg Pharma do?
Heidelberg Pharma AG is a company in the Healthcare sector, Biotechnology industry, headquartered in Germany.
The CEO is Dongzhou Liu, the company employs around 41 people.
The IPO was on 13/11/2006; the stock trades on XETRA under the ticker HPHA.DE.
When does Heidelberg Pharma report next?
The next earnings date is 03/02/2027.
Around past earnings, price swings were roughly 8% stronger than usual.
Does Heidelberg Pharma pay a dividend?
No, Heidelberg Pharma currently does not pay a dividend.
Which stocks are comparable to Heidelberg Pharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Heidelberg Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Heidelberg Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.